Research ArticleClinical Investigation
Fibroblast Activation Protein–Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel Wiesweg, Clemens Aigner, Till Plönes, Kaid Darwiche, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Rainer Hamacher, Wilfried E.E. Eberhardt, Martin Schuler, Ken Herrmann, Wolfgang P. Fendler and Hubertus Hautzel
Journal of Nuclear Medicine July 2024, jnumed.124.267473; DOI: https://doi.org/10.2967/jnumed.124.267473
Lukas Kessler
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2Institute of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
Felix Schwaning
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
Martin Metzenmacher
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
4Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Kim Pabst
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
Jens Siveke
4Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
5Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany;
6Division of Solid Tumor Translational Oncology, German Cancer Consortium, Partner Site Essen, Essen, Germany;
7German Cancer Research Center, Heidelberg, Germany;
Marija Trajkovic-Arsic
5Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany;
6Division of Solid Tumor Translational Oncology, German Cancer Consortium, Partner Site Essen, Essen, Germany;
7German Cancer Research Center, Heidelberg, Germany;
Benedikt Schaarschmidt
2Institute of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Marcel Wiesweg
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
4Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Clemens Aigner
8Department of Thoracic Surgery and Thoracic Endoscopy, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
9Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria;
Till Plönes
7German Cancer Research Center, Heidelberg, Germany;
8Department of Thoracic Surgery and Thoracic Endoscopy, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
10Division of Thoracic Surgery, Department of Visceral, Thoracic, and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;
11National Center for Tumor Diseases, Dresden, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; and Helmholtz-Zentrum Dresden–Rossendorf, Dresden, Germany;
Kaid Darwiche
12Department of Pulmonary Medicine, Section of Interventional Pulmonology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Servet Bölükbas
8Department of Thoracic Surgery and Thoracic Endoscopy, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Martin Stuschke
13Department of Radiotherapy, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Lale Umutlu
2Institute of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Michael Nader
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
Dirk Theegarten
14Institute of Pathology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany; and
Rainer Hamacher
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
4Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Wilfried E.E. Eberhardt
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
15Division of Thoracic Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany
Martin Schuler
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
4Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
Ken Herrmann
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
Wolfgang P. Fendler
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
Hubertus Hautzel
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site Essen, Essen, Germany;
SNMMI members
Login to the site using your SNMMI member credentials
Individuals
Login as an individual user
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 10
October 1, 2024
Fibroblast Activation Protein–Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel Wiesweg, Clemens Aigner, Till Plönes, Kaid Darwiche, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Rainer Hamacher, Wilfried E.E. Eberhardt, Martin Schuler, Ken Herrmann, Wolfgang P. Fendler, Hubertus Hautzel
Journal of Nuclear Medicine Jul 2024, jnumed.124.267473; DOI: 10.2967/jnumed.124.267473
Fibroblast Activation Protein–Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel Wiesweg, Clemens Aigner, Till Plönes, Kaid Darwiche, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Rainer Hamacher, Wilfried E.E. Eberhardt, Martin Schuler, Ken Herrmann, Wolfgang P. Fendler, Hubertus Hautzel
Journal of Nuclear Medicine Jul 2024, jnumed.124.267473; DOI: 10.2967/jnumed.124.267473
Jump to section
Related Articles
Cited By...
- No citing articles found.